SIGA Technologies Inc. (SIGA) Stock Price & How to Invest

SIGA Technologies is a commercial-stage pharmaceutical company built around one product, TPOXX (tecovirimat), an antiviral approved by the FDA to treat smallpox in both oral and intravenous forms. Because smallpox is eradicated in the wild, the real market is biodefense: governments stockpile TPOXX as a countermeasure against a deliberate or accidental release. SIGA's anchor customer is the US government through BARDA, which procures TPOXX for the Strategic National Stockpile under the 19C contract valued at up to roughly $629 million over a multi-year period. International governments in Europe, Asia-Pacific and elsewhere add incremental orders. In 2025 SIGA reported about $88 million in product revenue and roughly $24 million in pre-tax operating income, and it carries a strong balance sheet with well over $100 million in cash and no debt.

What makes SIGA unusual for a small biopharma is that it is consistently profitable and returns cash to shareholders through periodic special dividends rather than burning capital on a pipeline. The flip side is concentration: nearly all revenue comes from TPOXX, and the largest buyer is the US government, so results depend on the timing of a handful of large orders. Q1 2026 revenue fell to about $6.2 million with a small net loss, mainly because no international product sales landed in the quarter, while the company guided to more than $35 million of oral and IV TPOXX deliveries across the second and third quarters. SIGA is also working to broaden TPOXX's uses, including a smallpox post-exposure prophylaxis label and IV formulation growth, while navigating regulatory reviews in some regions that have questioned TPOXX's benefit specifically for mpox treatment.

SIGA carries unusually concentrated risk for its size. Nearly all revenue comes from a single product, TPOXX, so any efficacy, safety or manufacturing setback would hit the whole business. Customer concentration is just as acute: the US government is by far the largest buyer, and contract timing, budget cycles and renewal of the BARDA agreement dominate results, making revenue lumpy from quarter to quarter, as the weak Q1 2026 showed. Regulatory risk is real on the mpox front, where some agencies have reviewed and questioned TPOXX's benefit for mpox treatment even though the core smallpox approval stands. International orders are episodic and hard to forecast, and a stockpile-driven model means demand can plateau once buyers are supplied. Special dividends are discretionary and not guaranteed to recur.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see SIGA Technologies Inc.'s investor relations page or your broker.

• Business model: Single-product antiviral (TPOXX) sold mainly to governments
• 2025 product revenue: About $88 million (per company results)
• 2025 pre-tax operating income: Roughly $24 million (company disclosed)
• Q1 2026 revenue: About $6.2 million with a small net loss; no international sales that quarter
• Balance sheet: Cash-rich (well over $100 million) with no debt, per recent filings
• Capital return: Periodic special cash dividends ($0.60/share declared in early 2026 and in 2025)

SIGA's earnings are lumpy and contract-driven, so a single quarter can look very different from the full year. Revenue depends on when a handful of large government orders ship, which means trailing multiples built on one quarter can badly mislead in either direction. A quarter with no international shipments can show a loss even when the annual picture is profitable. Any valuation view should weigh the durability and timing of stockpile procurement, the net cash position and discretionary special dividends rather than a simple price-to-earnings figure. These figures are drawn from company disclosures and should be checked against the latest filings before acting.

There are three common ways to get SIGA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so SIGA sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where SIGA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

SIGA is a rare small biopharma that is profitable, debt-free and cash-rich, funded by government demand for its smallpox antiviral TPOXX. The trade-off is heavy dependence on a single product and a small set of government buyers, which makes revenue lumpy and contract timing the dominant driver.